Objective: To evaluate the efficacy and safety of intravenous regional anesthesia in the treatment of unilateral closed fractures and dislocations of forearm or wrist in children.
Design: A prospective study over 6 years.
Setting: The study was undertaken in the well-equipped emergency department of a community general hospital for ambulatory patients.
Patients: One hundred and thirty-nine children between the ages of 4 and 18 years with unilateral closed fractures and dislocations of forearm or wrist.
Intervention: All children received premedication with a combination of meperidine and promethazine (0.5 mg/kg intramuscularly) and regional upper limb anesthesia with 0.5% lidocaine solution (3 mg/kg intravenously) after inflation of an arm tourniquet.
Main Outcome Measures: The relief of pain, allowing closed reduction with intravenous regional anesthesia, and the incidence of complications.
Results: All patients had complete relief of pain allowing successful closed reduction in 133 patients (96%); tourniquet pain occurred in 10 patients (7%). There were no symptoms of lidocaine toxicity. There were no neurovascular or compartment syndrome complications.
Conclusions: Intravenous regional anesthesia for the treatment of fractures and dislocations of forearm and wrist in children was found to be simple, safe and effective.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Gaps in knowledge and management of iron deficiency in heart failure: a nationwide survey of cardiologists in China.
Heart
January 2025
Heart Failure Center, Department of Cardiology, China-Japan Friendship Hospital, Beijing, China
Background: Heart failure (HF) guidelines recommend routine testing for iron deficiency (ID) and, for those with ID, intravenous iron if the left ventricular ejection fraction is <50%. Guideline adherence to these recommendations by cardiologists in China is unknown.
Methods And Results: An independent academic web-based survey was designed and distributed via social networks to cardiologists across China.
Intravenous lidocaine for the treatment of sepsis-associated encephalopathy: a retrospective cohort study.
Neurol Res
January 2025
Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Anesthesia Management, Urumqi, Xinjiang, China.
Objective: This study aimed to evaluate the efficacy of intraoperative intravenous lidocaine administration in the management of sepsis-associated encephalopathy (SAE).
Methods: This retrospective cohort analysis included 165 patients diagnosed with SAE, who were categorized into two groups: the lidocaine group ( = 55) and the control group ( = 110). The lidocaine group received an intravenous injection of lidocaine at 1.
Geographical location of ischemic stroke patients affects thrombolysis availability in Denmark.
J Neurol Sci
January 2025
Pre-Hospital Center, Region Zealand, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic address:
Introduction: Early recognition and treatment of stroke is paramount for good outcome. Transport distance may result in delayed arrival for revascularization therapy. We investigated how transport time and distance to the revascularization unit affected the probability of receiving intravenous thrombolysis in Denmark between 2015 and 2020, for patients calling the Emergency Medical Services within three hours of symptom onset.
View Article and Find Full Text PDFBackground: Intrathecally (IT) delivered antisense oligonucleotides (ASOs) are promising therapies that can reduce tau pathology in Alzheimer's Disease (AD). However, current plasma and CSF sampling methods to estimate brain tissue exposure of ASOs are inherently limited, hampering ASO clinical developmental plans. We developed the PET tracer [F]BIO-687, which binds ASO conjugates (ASO-Tz) in vivo, allowing us to image ASO distribution in a living brain using "pretargeted" imaging.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
University of Southern California, Los Angeles, CA, USA.
Background: Disease-modifying treatments for Alzheimer's disease (AD) are becoming available. To date, all current treatments require intravenous infusion, and concerns have emerged that lack of infusion capacity may limit access to treatment. We predict supply and demand for infusions for AD treatment in the US under different assumptions over a 10-year period.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!